Cancer Cell Analysis Market Booms as the Disease Persists

December 27, 2018

WELLESLEY, Mass., Dec. 27, 2018 – The global cancer cell analysis market has grown exponentially in recent years due to the rising prevalence of various cancers across the globe, surging investments for cancer-based research, growing importance of cell assay-based drug development, rising demand for personalized cancer medicine development, and advancements in both stem cell analysis and biomarker technology. 

The global market for cancer cell analysis was valued at $7.4 billion in 2018 and is expected to reach $10.8 billion by 2023 at a compound annual growth rate (CAGR) of 7.8%, according to the report “Cancer Cell Analysis, Instruments, Consumables and Reagents.”

Critical players in the market include Bio-Rad Laboratories Inc. (BIO), Illumina Inc. (ILMN)  Sphere Fluidics Inc., Becton Dickinson & Company (BDX), Merck KGaA (MKGAF), Qiagen Ltd., BioTek Instruments Inc. and Merck Millipore Ltd.

Research Highlights:

  • Some of the current technologies cancer cell analysis technologies include spectrophotometry, cell imaging, polymerase chain reaction (PCR), blotting, high content screening (HCS), cell microarrays, centrifugation, flow cytometry and cell counting. 
  • The governments of various countries including the U.S., the UK, and Australia, among others, are highly determined to fight against cancer and thus are investing heavily in cancer-based research programs. 
  • According to the Pharmaceutical Research and Manufacturers of America, over 25% of novel drugs that received FDA approval in 2016 were considered personalized medicines. 

Cancer cell analysis helps in the investigation of basic cancerous cell biology, its relation to disease and the development of novel small molecule, cell-based therapies and biotherapeutics for cancer,” BCC Research analyst Sathya Durga said.

North America Dominates Cancer Cell Analysis Market

North America dominated the market for cancer cell analysis in 2017 with total revenue of $2.3 billion. The dominance of North America is justified by the presence of a wide pool of market players offering their products in cancer cell analysis. In addition, the high prevalence of cancer coupled with significant investments in the stem cell and cancer-based research also drive the North American market for cancer cell analysis. 

Editors/reporters requesting analyst interviews should contact Eric Surber at

Cancer Cell Analysis, Instruments, Consumables and Reagents( BIO177A )
Publish Date: Dec 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.